Weight-related conditions that may support eligibility include hypertension, prediabetes, type 2 diabetes, high cholesterol, obstructive sleep apnea, and cardiovascular disease
These medications reduce appetite, increase satiety, and support sustainable weight loss
Qualifying Comorbidities FDA labeling and clinical guidelines commonly recognize: Hypertension (blood pressure 130/80 or taking antihypertensive medication) Type 2 diabetes (HbA1c 6.5% or on glucose-lowering medication) Prediabetes (HbA1c 5.7-6.4% or impaired fasting glucose) Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides) Obstructive sleep apnea (diagnosed via sleep study) Cardiovascular disease (prior MI, stroke, coronary artery disease) Non-alcoholic fatty liver disease / MASLD Polycystic ovary syndrome (PCOS) with metabolic features Osteoarthritis weight-bearing joints Insurance formularies may be stricter some require objective documentation (lab values, sleep study reports) rather than self-report
The new weight loss medications are approved by the Food and Drug Administration (FDA) only for obesity, which the agency defines as a body mass index of 30 or greater
Should clinicians screen for depression in patients starting GLP1 therapy
Our study, which included a larger and more diverse real-world population with a longer follow-up duration, demonstrated significant psychiatric risks
